Protocole National de Diagnostic et de Soins (PNDS) Déficits du Cycle de l'Urée

Argumentaire

Filière de Santé Maladies Rares G2M

Mai 2021

Cet argumentaire a été élaboré par le centre de référence des Maladies Héréditaires du Métabolisme CHU
Jeanne de Flandre Lille. Il a servi de base à l'élaboration du PNDS du Cycle de l'Urée.
Le PNDS est téléchargeable sur le site de la filière G2M
<http://www.filiere-g2m.fr/>

Sommaire

Liste des abréviations	4
Préambule	6
Argumentaire	8
1 Stratégie de recherche bibliographique.....	8
2 Synthèse bibliographique	8
2.1 Recommandations de bonnes pratiques	8
2.2 Revues systématiques de la littérature	13
2.3 Etudes cliniques	14
Annexe 1. Recherche documentaire et sélection des articles	15
Annexe 2. Liste des participants.....	16
Annexe 3. Références bibliographiques	18

Liste des abréviations

AAH : allocation aux adultes handicapés
ACS : aide à la complémentaire santé
AEEH : allocation d'éducation de l'enfant handicapé
AESH : accompagnant d'élève en situation de handicap (anciennement AVS)
AJPP : allocations journalières de présence parentale
ALD : affection de longue durée
AMM : acidémie méthylmalonique
ANC : apports nutritionnels conseillés
ANSM : agence nationale de sécurité du médicament et des produits de santé
AP : acidémie propionique
ARG1D : déficit en arginase 1
ASLD : déficit en argininosuccinate lyase/argininosuccinylurie
ASSD : déficit en argininosuccinate synthétase/citrullinémie de type I
ATU : autorisation temporaire d'utilisation
AVS : auxiliaire de vie scolaire
CAVAD : déficit en anhydrase carbonique Va
CCMR : centre de compétence maladies rares
CDAPH : commission des droits et de l'autonomie des personnes handicapées
CEAM : carte européenne d'assurance maladie
CNAMTS : caisse nationale d'assurance maladie des travailleurs salariés
CPDPN : centre pluridisciplinaire de diagnostic prénatal
CPS1D : déficit en carbamyl phosphate synthétase 1
CRMR : centre de référence maladies rares
CVVHDF : hémodiafiltration continue veino-veineuse
DADFMS : denrées alimentaires destinées à des fins médicales spéciales
DCI : dénomination commune internationale
DGP : diagnostic prénatal
ESAT : établissement et service d'aide par le travail
ETP : éducation thérapeutique du patient
FAM : foyer d'accueil médicalisé
HD : hémodialyse
i.m : intra-musculaire
i.v : intra-veineux
IRM : imagerie par résonance magnétique
KTC : cathéter central
MAS : maison d'accueil spécialisée
MDPH : maison départementale des personnes handicapées
MPR : médecine physique et de réadaptation
NAA : N-acétyl aspartate
NAGSD : déficit en N-acétylglutamate synthase
NE : nutrition entérale
NEDC : nutrition entérale à débit continu
NGS : « next-generation sequencing », le séquençage haut débit
ORNT1 : antiport ornithine-citrulline mitochondrial
OTCD : déficit en ornithine transcarbamylase

PAI : projet d'accueil individualisé
PCH : prestation de compensation du handicap
PEAtc : potentiels évoqués auditifs du tronc cérébral
PEV : potentiels évoqués visuels
PIRES : protocole inter régimes d'examens spéciaux
PNDS : protocole national de diagnostic et de soins
PPS : projet personnalisé de scolarisation
RNP : références nutritionnelles pour la population
RQTH : reconnaissance de la qualité de travailleur handicapé
SESSAD : service d'éducation spéciale et de soins à domicile
SMR : spectroscopie par résonance magnétique
SNG : sonde naso-gastrique
Syndrome triple H : syndrome d'hyperornithinémie-hyperammoniémie-homocitrullinurie
UCD : « Urea Cycle Disorders », Déficits du Cycle de l'Urée
VMO : vitamines, minéraux et oligo-éléments

Préambule

Le présent protocole national de diagnostic et de soins (PNDS) a pour objectif de présenter aux professionnels de santé la prise en charge optimale et le parcours de soins d'un patient atteint d'un déficit du cycle de l'urée. Il vise à leur donner les outils qui permettent d'évoquer et de confirmer le diagnostic, de prévenir les séquelles neurologiques, de poser les indications thérapeutiques, de définir les modalités et l'organisation du suivi.

Il s'agit d'un outil pragmatique auquel le médecin peut se référer pour la prise en charge de cette maladie, notamment au moment d'établir le protocole de soins avec le médecin conseil et le patient dans le cadre de l'admission en affection longue durée (ALD) n°17, relative aux maladies héréditaires du métabolisme.

Le PNDS ne peut cependant pas envisager tous les cas spécifiques, toutes les comorbidités, toutes les particularités thérapeutiques et tous les protocoles de soins hospitaliers, ni se substituer à la responsabilité individuelle du médecin vis-à-vis de son patient.

Le PNDS sur les déficits du cycle de l'urée a été élaboré selon la « méthode d'élaboration d'un protocole national de diagnostic et de soins pour les maladies rares » publiée par la Haute Autorité de Santé en 2012 (guide méthodologique disponible sur le site de la HAS : www.has-sante.fr). Le présent argumentaire comporte l'ensemble des données bibliographiques analysées pour la rédaction du PNDS.

Le projet de ce PNDS a été porté par le CRMR Maladies Héréditaires du Métabolisme (MHM) de l'Hôpital Jeanne de Flandre, CHU de Lille, sous l'égide de la filière G2M.

Le groupe de rédaction est composé de médecins pédiatre et adulte spécialisés, biochimistes, psychologues ainsi que des diététicien(ne)s expert(e)s dans la prise en charge de cette maladie. Chacun est issu d'un centre de référence ou de compétence en maladies héréditaires du métabolisme, et affilié à la filière G2M et à la Société Française des Erreurs Innées du Métabolisme (SFEIM).

Après analyse et synthèse de la littérature médicale et scientifique pertinente, les rédacteurs ont établi le plan et rédigé les chapitres d'une version préliminaire du PNDS. L'intégralité de cette version préliminaire a été relue et commentée entre rédacteurs lors de visioconférences afin d'aboutir à une version 1 du PNDS.

Cette version 1 a alors été soumise à un groupe de lecture multidisciplinaire et multiprofessionnel. Les déficits du cycle de l'urée étant des maladies rares, à prise en charge essentiellement hospitalière et nécessitant l'intervention de nombreux professionnels médicaux et paramédicaux, la composition du groupe de lecture a cherché à regrouper :

- des professionnels de santé de filières maladies rares G2M assurant le diagnostic et le suivi de ces pathologies dans leur pratique hospitalière, issus de régions différentes, de spécialités pédiatriques et adultes.
- des professionnels de santé de spécialités différentes intervenant dans la prise en charge du patient (réanimateur, biochimistes, pharmacien).
- un représentant de la médecine de ville.
- un représentant d'une association de patients.

Les relecteurs ont été réunis lors de 2 sessions de visioconférences et ont donné leur avis sur le fond et la forme du document, en particulier sur la justesse, la lisibilité et l'applicabilité du PNDS. Les

commentaires du groupe de lecture ont ensuite été analysés et discutés entre relecteurs et rédacteurs, afin d'intégrer les corrections collégialement acceptées dans la version finale du PNDS.

Argumentaire

1 Stratégie de recherche bibliographique

Les déficits du cycle de l'urée ont fait l'objet de recommandations européennes en 2012 (méthodologie SIGN, Scottish Intercollegiate Guideline Network) par Häberle *et al* avec révisions en 2019 (méthodologie GRADE, Grading of Recommendations, Assessment, Development and Evaluation).

L'argumentaire du PNDS repose sur les recommandations révisées de 2019 :

Häberle J, Burlina A, Chakrapani A, et al. Suggested guidelines for the diagnosis and management of urea cycle disorders : first revision. J Inherit Metab Dis. 2019;42:1192–1230

Ces recommandations s'appuyaient sur la bibliographie existante jusqu'en 2018. Une mise à jour de la littérature a donc été effectuée avec recueil des quelques articles publiés entre 2018 et mai 2020, notamment sur la base de données PUBMED, à partir des mots clés.

2 Synthèse bibliographique

2.1 Recommandations de bonnes pratiques

Tableau 1. Recommandations de bonne pratique

Auteur, année, référence, pays	Objectif	Stratégie de recherche bibliographique renseignée (oui/non)*	Recueil de l'avis des professionnels (oui, non, lesquels)	Recueil de l'avis des patients (oui, non)	Populations et techniques (ou produits) étudiées	Résultats (avec grade des recommandations si disponible)
Häberle J et al, 2019	Réévaluer les recommandations existantes, les mettre à jour et proposer de nouvelles recommandations pour le diagnostic et la prise en charge des patients atteint d'un déficit du cycle de l'urée	<p>Oui</p> <p>Revue systématique de la littérature entre 2011 et 2018</p> <p>Bases de données MEDLINE, Embase, bibliothèque Cochrane, Medlink et Orphanet ainsi que les sites internet des sociétés nationales et internationales pour les maladies métaboliques congénitales</p> <p>Méthodologies SIGN (<i>Scottish Intercollegiate Guideline Network</i>) et GRADE (<i>Grading of Recommendations, Assessment, Development and Evaluation</i>)</p>	<p>Oui</p> <p>Réunion d'un groupe d'établissement des recommandations (GER) :</p> <p>17 experts internationaux en médecine métabolique, biochimie clinique, nutrition, néphrologie, et psychologie</p>	Oui	Patients atteints d'un déficit du cycle de l'urée	<p>R1 (modérée) : considérer un déficit du cycle de l'urée (à tout âge) en cas de détresse neurologique, de symptômes psychiatriques, d'insuffisance hépatique, de suspicion d'intoxication et en cas de DD (diagnostic différentiel ? abréviation à ajouter au début) d'une septicémie néonatale</p> <p>R2 (forte) : Toujours doser l'ammoniémie (attention aux recommandations pré-analytiques) en cas des conditions définies en R1</p> <p>R3 (modérée) : En cas d'hyperammoniémie, doser AAS (abréviation à ajouter au début) et faire un profil des acylcarnitines et commencer le traitement d'emblée sans attendre les résultats</p> <p>R4 (modérée) : DD sepsis néonatal !</p> <p>R5 (modérée) : Confirmation d'un déficit du cycle de l'urée par biologie moléculaire</p> <p>R6 (forte) : Diagnostic prénatal de préférence par analyse génétique moléculaire</p> <p>R7 (modérée) : Dépistage néonatal pose problème</p> <p>R8 (modérée) : Arrêter le catabolisme protéidique et mise en route immédiate du traitement de détoxification de l'ammoniac</p> <p>R9 (modérée) : Préparation d'emblée d'une éventuelle épuration extracorporelle</p> <p>R10 (faible) : Chez l'adulte, considérer l'épuration extracorporelle en première ligne</p> <p>R11 (forte) : Hémodiafiltration à prioriser, transfusion <u>déconseillée</u></p>
Filière de Santé	Maladies Rares G2M / mai 2021

<p>R12 (modérée) : Perfusion de serum glucosé polyionique à forte dose avec lipides (après avoir éliminé un trouble de la B-oxidation des acides gras). Limitation de la durée de l'arrêt d'apport en protéines (24-48h maximum ?)</p> <p>R13 (modérée) : Maintien essentiel d'un équilibre métabolique nutritionnel</p> <p>R14 (modérée) : Mélange des acides aminés essentiels est indispensable surtout en cas de tolérance protidique basse et prise de phénylbutyrate</p> <p>R15 (modérée) : ETP indispensable devant le traitement diététique au long court</p> <p>R16 (faible) : L'utilisation d'une nutrition entérale par sonde doit être évaluée</p> <p>R17 (faible-moderée) : Documents écrits sur le traitement destinés au personnel soignant</p> <p>R18 (modérée) : Chélateurs d'azote recommandés et prescrits au cas par cas</p> <p>R19 (faible) : En cas de grossesse, le benzoate de sodium est recommandé</p> <p>R20 (modérée) : Supplémentation en L-arginine et/ou L-citrulline fortement recommandée. La L-arginine est contre-indiquée en cas de ARG1D</p> <p>R21 (forte) : L'utilisation de N-Carbamyl-L-glutamate est recommandée comme traitement de première ligne en cas de NAGSD</p> <p>R22 (faible) : La vaccination selon le schéma national est recommandée</p> <p>R23 (opinion expert) : Une chirurgie électorive est programmée dans un CR MHM (avec fiche d'urgence)</p> <p>R24 (modérée) :</p>
--	--	--	--	--	--	---

<p>Greffe hépatique à considérer en cas de mauvaise réponse/compliance thérapeutique, qualité de vie médiocre, sans atteinte neurologique</p> <p>R25 (modérée/forte) :</p> <p>La greffe hépatique doit se faire avant l'instauration d'une éventuelle atteinte neurologique (idéalement entre 3 et 12 mois de vie).</p> <p>Greffe hépatique recommandée devant une atteinte hépatique progressive et/ou décompensations récurrentes malgré TTT (abréviation à définir au début) médical optimal standard</p> <p>R26 (opinion expert) :</p> <p>Un monitoring clinique, biochimique et nutritionnel est essentiel</p> <p>R27 (forte) :</p> <p>Seuils recommandés : ammoniac <80 µmol/L, glutamine <1000 µmol/L, Arginine, EAA et BCAA (abréviations à définir au début) dans la fourchette des normes</p> <p>R28 (modérée) :</p> <p>IRM cérébrale (de préférence avec spectroscopie) recommandée</p> <p>R29 (modérée) :</p> <p>Evaluation du QI (abréviation à définir au début) et testing neuropsychologique recommandés</p> <p>R30 (forte) :</p> <p>Suivi psychologique et encadrement des familles fortement recommandés</p> <p>R32 (forte) :</p> <p>Traitement par carbamylglutamate exclusif en cas de NAGSD</p> <p>R33 (forte) :</p> <p>Pour l'OTCD, recours à la biologie moléculaire en première intention. Si non contributif, les essais enzymatiques sur plasma, foie ou intestin sont recommandés</p> <p>R34 (forte) :</p>
--	--	--	--	--	--

<p>En cas de citrullinémie de type 1, la biologie moléculaire est fortement recommandée à but thérapeutique et prénatal</p> <p>R35 (forte) :</p> <p>En cas de ASLD, la recherche de l'ASA (abréviation à définir au début) est recommandée, Puis la biologie moléculaire pour le conseil génétique et à but prénatal</p> <p>R36 (modérée) :</p> <p>L'utilisation de la L-arginine à forte dose est déconseillée en cas de ASLD à risque des complications neurologiques et hépatiques</p> <p>R37 (modérée) :</p> <p>En cas de ARG1D, le traitement de routine (comme pour tout autre UCD) est recommandé, SANS utiliser d'arginine</p> <p>R38 (modérée) :</p> <p>En cas de syndrome de HHH, un régime hypoprotidique et une supplémentation par citrulline ou arginine sont recommandés</p>
Summar M et al, 2008	Registre international	registre	oui	260 patients (1982-2003)	2/3 late onset UCDs

Häberle J, Burlina A, Chakrapani A, et al. Suggested guidelines for the diagnosis and management of urea cycle disorders: First revision. J Inher Metab Dis. 2019;42:1192-1230.

Summar ML, Dobbelaere D, Brusilow S, Lee B. Diagnosis, symptoms, frequency and mortality of 260 patients with urea cycle disorders from a 21-year, multicentre study of acute hyperammonaemic episodes. Acta Paediatr. 2008;97(10):1420-1425.

2.2 Revues systématiques de la littérature

Tableau 2. Revues systématiques de la littérature
Auteur, année, référence, pays	Objectif	Stratégie de recherche renseignée (oui/non)*	Critères de sélection des études	Populations et techniques (ou produits) étudiées	Critères d'évaluation	Résultats et signification
Maillot F et al, 2016	Revue Française	Population UCD adulte	Etude rétrospective	Revue de la Prise en charge adulte en France
McKiernan PJ, 2021	1. moment d'indication de greffe 2. outcome 3. facteurs de prédiction de survie	Revue de l'expérience américaine de la greffe hépatique dans les maladies métaboliques	Etude américaine	5996 patients	Etude rétrospective (1987-2017)	Enfants : greffe x 6 Adulte : statut quo
Stepien KM, 2019	Revue internationale	Population UCD adulte	Etude rétrospective	Approche d'un management systématique
Moreau C, 2019	Revue Langue Française	Femmes UCDs enceintes	Etude rétrospective	Suivi multidisciplinaire recommandée

* date de début et fin de la recherche, bases de données, mots clés renseignés

Maillot F, Blasco H, Lioger B, Bigot A, Douillard C. Diagnosis and treatment of urea cycle disorders in adult patients. Rev Med Interne. 2016;37:680-684.

Patrick J McKiernan, Armando Ganoza, James E. Squires et al. Evolving trends in liver transplant for metabolic liver disease in the United States. Liver Transpl 2019 Jun;25(6):911-921. doi: 10.1002/lt.25433

Stepien KM, Geberhiwot T, Hendriksz CJ, Treacy EP. Challenges in diagnosing and managing adult patients with urea cycle disorders. J Inher Metab Dis. 2019 Nov;42(6):1136-1146. doi: 10.1002/jimd.12096. Epub 2019 May 8. PMID: 30932189.

Moreau C, Joueidi Y, Peoc'h K, Bardou-Jacquet E, Le Lous M, Bendavid C, Lavoué V, Damaj L, Dessein AF. Grossesse en cas de maladies métaboliques à expression hépatique : quels risques pour la mère et l'enfant ? Ann Biol Clin 2019 ; 77(6) : 605-18

2.3 Etudes cliniques

Tableau 3. Etudes cliniques
Auteur, année, référence, pays	Objectif	Méthodologie, niveau de preuve	Population	Intervention	Critères de jugement	Résultats et signification
Husson MC et al, 2016	Etude rétrospective	61 patients UCD (2000-2010)	Benzoate de sodium est sûr et efficace
Boneh A, 2014	Etude rétrospective	Relecture des régimes alimentaires	28 patients	Recommandations sur des apports et compositions alimentaires

Husson MC, Schiff M, Fouilhoux A, Cano A, Dobbelaere D, Brassier A, Mention K, Arnoux JB, Feillet F, Chabrol B, Guffon N, Elie C, de Lonlay P. Efficacy and safety of i.v. sodium benzoate in urea cycle disorders: a multicentre retrospective study. *Orphanet J Rare Dis.* 2016 Sep 23;11(1):127.

Boneh A. Dietary protein in urea cycle defects: How much? Which? How? *Mol Genet Metab.* 2014 Sep-Oct;113(1-2):109-12. doi: 10.1016/j.ymgme.2014.04.009. Epub 2014 May 10. PMID: 24857408.

Annexe 1. Recherche documentaire et sélection des articles

Recherche documentaire

Sources consultées	Bases de données : Medline, Embase, the Cochrane Library, Medlink, Pubmed Sites internet : Orphanet
Période de recherche	2008-2020
Langues retenues	Anglais, Français
Mots clés utilisés	Troubles du cycle de l'urée, UCD, ammoniac, N-acétylglutamate synthase, carbamyl phosphates synthétase, ornithine carbamyl transférase, argininosuccinate synthétase, argininosuccinate lyase, arginase-1, syndrome d'hyperornithinémie-hyperammoniémie-homocitrullinurie (syndrome triple H)
Nombre d'études recensées	345
Nombre d'études retenues	8

Critères de sélection des articles

Les déficits du cycle de l'urée ayant fait l'objet de recommandations Européennes révisées en 2019 (Haberle et al, 2019), les articles les plus récents et les plus pertinents ont été retenus à partir de 2018.

Annexe 2. Liste des participants

Ce travail a été coordonné par le **Dr. Dries DOBBELAERE**, coordonnateur du Centre de Référence des Maladies Héréditaires du Métabolisme, CHU Lille, Hôpital Jeanne de Flandre, Lille

Ont participé à l'élaboration du PNDS :

Rédacteurs (ordre alphabétique)

- **Mme Valérie Barbier, psychologue, Paris.** Centre de Référence constitutif, Maladies Héréditaires du Métabolisme, CHU Necker-Enfants Malades
- **Mme Claire Belloche, diététicienne, Paris.** Centre de Référence constitutif, Maladies Héréditaires du Métabolisme, CHU Necker-Enfants Malades
- **Pr Jean-François Benoist, biochimiste, Paris.** Laboratoire de Biochimie métabolomique, Centre de Référence constitutif, Maladies Héréditaires du Métabolisme, CHU Necker-Enfants Malades,
- **Pr Pascale de Lonlay, pédiatre métabolicien, Paris.** Centre de Référence constitutif, Maladies Héréditaires du Métabolisme, CHU Necker-Enfants Malades, AP-HP. Coordinatrice de la filière maladies rares G2M.
- **Dr Dries Dobbelaere, pédiatre métabolicien, Lille.** Centre de référence constitutif, Maladies Héréditaires du Métabolisme, CHU Lille
- **Mr Laurent François, diététicien, Paris.** Centre de Référence constitutif, Maladies Héréditaires du Métabolisme, CHU Necker-Enfants Malades
- **Dr Apolline Imbard, biochimiste, Paris.** Laboratoire de Biochimie métabolomique, Centre de Référence constitutif, Maladies Héréditaires du Métabolisme, CHU Necker-Enfants Malades
- **Mme. Claire Jonvel, psychologue, Lille.** Centre de référence constitutif, Maladies Héréditaires du Métabolisme, CHU Lille
- **Dr Florence Lacaille, hépatologue, Paris.** CHU Necker-Enfants Malades, AP-HP, 75015 PARIS.
- **Dr Esther Noel,** Centre de Compétence Maladies Héréditaires du Métabolisme, CHU de Strasbourg
- **Mr William Perret, diététicien, Bordeaux,** Centre de Compétence Maladies Héréditaires du Métabolisme, CHU Bordeaux
- **Dr Samia Pichard, pédiatre métabolicien, Paris.** Centre de Référence Maladies Héréditaires du Métabolisme, CHU Necker-Enfants Malades, AP-HP, 75015 PARIS.
- **Dr. Gustavo SOTO ARES, neuroradiologue, Lille.** CHU Lille

Groupe de travail multidisciplinaire de relecture.

- **Association les Enfants du Jardin**
- **Dr Jean-Baptiste Arnoux, pédiatre métabolicien, Paris.** Centre de Référence Maladies Héréditaires du Métabolisme, CHU Necker-Enfants Malades, AP-HP, 75015 PARIS.
- **Dr Juliette Bouchereau, pédiatre métabolicien, Paris.** Centre de Référence Maladies Héréditaires du Métabolisme, CHU Necker-Enfants Malades, AP-HP, 75015 PARIS.
- **Mme Anne Debrabander, diététicienne.** Centre de référence constitutif, Maladies Héréditaires du Métabolisme, CHU Lille
- **Dr Roselyne Garnotel, Biochimiste, Reims.** Centre de Compétence constitutif, Maladies Héréditaires du Métabolisme, CHU Reims
- **Dr Marie Joncquel, biochimiste, Lille.** Centre de Référence constitutif, Maladies Héréditaires du Métabolisme, CHU Lille
- **Dr Benoit Leroy, médecin généraliste, Saint-Omer.**

Gestion des intérêts déclarés

Tous les participants à l'élaboration du PNDS sur les Déficits du Cycle de l'Urée ont rempli une déclaration d'intérêt disponible sur le site internet <http://www.filiere-g2m.fr/>

Les déclarations d'intérêt ont été analysées et prises en compte, en vue d'éviter les conflits d'intérêts, conformément au guide HAS « Guide des déclarations d'intérêts et de gestion des conflits d'intérêts » (HAS, 2010).

Modalités de concertation du groupe de travail multidisciplinaire

Télé/visioconférences :

04/09/2020

25/11/2020

23/02/2021

02/03/2021

08/03/2021

Annexe 3. Références bibliographiques

1. Häberle J, Boddaert N, Burlina A, et al. Suggested guidelines for the diagnosis and management of urea cycle disorders. *Orphanet J Rare Dis*. 2012;7:32.
2. Häberle J, Burlina A, Chakrapani A, et al. Suggested guidelines for the diagnosis and management of urea cycle disorders : first revision. *J Inher Metab Dis*. 2019;42:1192–1230
3. Dionisi-Vici C, Rizzo C, Burlina AB, et al. Inborn errors of metabolism in the Italian pediatric population: a national retrospective survey. *J Pediatr*. 2002;140(3):321-327.
4. Summar ML, Koelker S, Freedenberg D, et al. The incidence of urea cycle disorders. *Mol Genet Metab*. 2013;110(1–2):179-180.
5. Häberle J, Huemer M. Evaluation of implementation, adaptation and use of the recently proposed urea cycle disorders guidelines. *JIMD Rep*. 2015;21:65-70.
6. Bachmann C. Outcome and survival of 88 patients with urea cycle disorders: a retrospective evaluation. *Eur J Pediatr*. 2003; 162(6):410-416.
7. Nassogne MC, Heron B, Touati G, Rabier D, Saudubray JM. Urea cycle defects: management and outcome. *J Inher Metab Dis*. 2005;28(3):407-414.
8. Msall M, Batshaw ML, Suss R, Brusilow SW, Mellits ED. Neurologic outcome in children with inborn errors of urea synthesis. Outcome of urea cycle enzymopathies. *N Engl J Med*. 1984;310 (23):1500-1505.
9. Maestri NE, Clissold D, Brusilow SW. Neonatal onset ornithine transcarbamylase deficiency: a retrospective analysis. *J Pediatr*. 1999;134(3):268-272.
10. Unsinn C, Das A, Valayannopoulos V, et al. Clinical course of 63 patients with neonatal onset urea cycle disorders in the years 2001-2013. *Orphanet J Rare Dis*. 2016;11(1):116.
11. Nettesheim S, Kolker S, Karall D, et al. Incidence, disease onset and short term outcome in urea cycle disorders cross border surveillance in Germany, Austria and Switzerland. *Orphanet J Rare Dis*. 2017;12(1):111.
12. Burgard P, Kölker S, Haegi G, Lindner M, Hoffmann GF. Neonatal mortality and outcome at the end of the first year of life in early onset urea cycle disorders review and meta-analysis of observational studies published over more than 35 years. *J Inher Metab Dis*. 2016;39(2):219-229.
13. Harada E, Nishiyori A, Tokunaga Y, et al. Late onset ornithine transcarbamylase deficiency in male patients: prognostic factors and characteristics of plasma amino acid profile. *Pediatr Int*. 2006;48(2):105-111.
14. Serrano M, Perez-Duenas B, Gomez-Lopez L, et al. Neuropsychiatric manifestations in late onset urea cycle disorder patients. *J Child Neurol*. 2010;25:352-358.
15. Cavicchi C, Donati M, Parini R, et al. Sudden unexpected fatal encephalopathy in adults with OTC gene mutations clues for early diagnosis and timely treatment. *Orphanet J Rare Dis*. 2014; 9:105.
16. Enns GM. Neurologic damage and neurocognitive dysfunction in urea cycle disorders. *Semin Pediatr Neurol*. 2008;15(3):132-139.
17. Hediger N, Landolt MA, Diez-Fernandez C, Huemer M, Häberle J. The impact of ammonia levels and dialysis on outcome in 202 patients with neonatal onset urea cycle disorders. *J Inher Metab Dis*. 2018;41(4):689-698.
18. Nicolaidis P, Liebsch D, Dale N, Leonard J, Surtees R. Neurological outcome of patients with ornithine carbamoyltransferase deficiency. *Arch Dis Child*. 2002;86(1):54-56.
19. Kido J, Nakamura K, Mitsubuchi H, et al. Long term outcome and intervention of urea cycle disorders in Japan. *J Inher Metab Dis*. 2012;35(5):777-785.
20. Picca S, Dionisi-Vici C, Abeni D, et al. Extracorporeal dialysis in neonatal hyperammonemia: modalities and prognostic indicators. *Pediatr Nephrol*. 2001;16(11):862-867.
21. Erez A. Argininosuccinic aciduria: from a monogenic to a complex disorder. *Genet Med*. 2013;15(4):251-257.

22. van Karnebeek CD, Sly WS, Ross CJ, et al. Mitochondrial carbonic anhydrase VA deficiency resulting from CA5A alterations presents with hyperammonemia in early childhood. *Am J Hum Genet.* 2014;94(3):453-461.
23. Vockley J, Chapman KA, Arnold GL. Development of clinical guidelines for inborn errors of metabolism: commentary. *Mol Genet Metab.* 2013;108(4):203-205.
24. Brusilow S, Horwich A. Urea cycle enzymes. In: Scriver C, Beaudet A, Sly W, Valle D, eds. *The Metabolic & Molecular Bases of Inherited Disease.* 8th ed. New York, NY: McGraw- Hill; 2001:1909-1963.
25. Gropman AL, Summar M, Leonard JV. Neurological implications of urea cycle disorders. *J Inherit Metab Dis.* 2007;30(6): 865-879.
26. Trevisson E, Salvati L, Baldoin MC, et al. Argininosuccinate lyase deficiency: mutational spectrum in Italian patients and identification of a novel ASL pseudogene. *Hum Mutat.* 2007;28(7): 694-702.
27. Leonard JV, Morris AA. Urea cycle disorders. *Semin Neonatol.* 2002;7(1):27-35.
28. Ah Mew N, Simpson KL, Gropman AL, Lanpher BC, Chapman KA, Summar ML. Urea cycle disorders overview. In: Pagon RA, Adam MP, Ardinger HH, et al., eds. *GeneReviews(R).* Seattle (WA): University of Washington, Seattle; 1993. Last Update: June 22, 2017.
29. Rüegger CM, Lindner M, Ballhausen D, et al. Cross-sectional observational study of 208 patients with non-classical urea cycle disorders. *J Inherit Metab Dis.* 2014;37(1):21-30.
30. Martinelli D, Diodato D, Ponzi E, et al. The hyperornithinemia, hyperammonemia-homocitrullinuria syndrome. *Orphanet J Rare Dis.* 2015;10:29.
31. Deutsch SI, Burket JA, Rosse RB. Valproate-induced hyperammonemic encephalopathy and normal liver functions: possible synergism with topiramate. *Clin Neuropharmacol.* 2009;32(6): 350-352.
32. Smith W, Kishnani PS, Lee B, et al. Urea cycle disorders: clinical presentation outside the newborn period. *Crit Care Clin.* 2005;21 (4 suppl):S9-S17.
33. Kvedar JC, Baden HP, Baden LA, Shih VE, Kolodny EH. Dietary management reverses grooving and abnormal polarization of hair shafts in argininosuccinase deficiency. *Am J Med Genet.* 1991;40(2):211-213.
34. Patel HP, Unis ME. Pili torti in association with citrullinemia. *J Am Acad Dermatol.* 1985;12(1 Pt 2):203-206.
35. Cowley DM, Bowling FG, McGill JJ, van Dongen J, Morris D. Adult onset arginase deficiency. *J Inherit Metab Dis.* 1998;21(6): 677-678.
36. Crombez EA, Cederbaum SD. Hyperargininemia due to liver arginase deficiency. *Mol Genet Metab.* 2005;84(3):243-251.
37. Salvi S, Santorelli FM, Bertini E, et al. Clinical and molecular findings in hyperornithinemia-hyperammonemia-homocitrullinuria syndrome. *Neurology.* 2001;57(5):911-914.
38. Cartagena A, Prasad AN, Rupa CA, et al. Recurrent encephalopathy: NAGS (N-acetylglutamate synthase) deficiency in adults. *Can J Neurol Sci.* 2013;40(1):3-9.
39. Ah Mew N, Krivitzky L, McCarter R, Batshaw M, Tuchman M, Urea Cycle Disorders Consortium of the Rare Diseases Clinical Research Network. Clinical outcomes of neonatal onset proximal versus distal urea cycle disorders do not differ. *J Pediatr.* 2013; 162(2):324-329. e321.
40. Teufel U, Weitz J, Flechtenmacher C, et al. High urgency liver transplantation in ornithine transcarbamylase deficiency presenting with acute liver failure. *Pediatr Transplant.* 2011;15: E110-E115.
41. Fecarotta S, Parenti G, Vajro P, et al. HHH syndrome (hyperornithinaemia, hyperammonaemia, homocitrullinuria), with fulminant hepatitis-like presentation. *J Inherit Metab Dis.* 2006;29 (1):186-189.
42. Ito S, Kurasawa G, Yamamoto K, et al. A pregnant patient with fulminant hepatic failure was found to carry a novel missense mutation in the argininosuccinate synthetase gene. *J Gastroenterol.* 2004;39(11):1115-1117.

43. Mhanni AA, Chan A, Collison M, et al. Hyperornithinemia, hyperammonemia, homocitrullinuria syndrome (HHH) presenting with acute fulminant hepatic failure. *J Pediatr Gastroenterol Nutr.* 2008;46(3):312-315.
44. Faghfoury H, Baruteau J, de Baulny HO, Häberle J, Schulze A. Transient fulminant liver failure as an initial presentation in citrullinemia type I. *Mol Genet Metab.* 2011;102(4):413-417.
45. de Groot MJ, Cuppen M, Eling M, et al. Metabolic investigations prevent liver transplantation in two young children with citrullinemia type I. *J Inherit Metab Dis.* 2010;33(suppl 3):S413- S416.
46. Laemmle A, Gallagher RC, Keogh A, et al. Frequency and pathophysiology of acute liver failure in ornithine Transcarbamylase deficiency (OTCD). *PLoS One.* 2016;11(4):e0153358.
47. Gallagher RC, Lam C, Wong D, Cederbaum S, Sokol RJ. Significant hepatic involvement in patients with ornithine transcarbamylase deficiency. *J Pediatr.* 2014;164(4):720-725 e726.
48. Al-Hassnan ZN, Rashed MS, Al-Dirbashi OY, Patay Z, Rahbeeni Z, Abu-Amero KK. Hyperornithinemia, hyperammonemia, homocitrullinuria syndrome with stroke-like imaging presentation: clinical, biochemical and molecular analysis. *J Neurol Sci.* 2008;264(1-2):187-194.
49. Choi JH, Kim H, Yoo HW. Two cases of citrullinaemia presenting with stroke. *J Inherit Metab Dis.* 2006;29(1):182-183.
50. Christodoulou J, Qureshi IA, McInnes RR, Clarke JT. Ornithine transcarbamylase deficiency presenting with strokelike episodes. *J Pediatr.* 1993;122(3):423-425.
51. Keegan CE, Martin DM, Quint DJ, Gorski JL. Acute extrapyramidal syndrome in mild ornithine transcarbamylase deficiency: metabolic stroke involving the caudate and putamen without metabolic decompensation. *Eur J Pediatr.* 2003;162(4):259-263.
52. Sperl W, Felber S, Skladal D, Wermuth B. Metabolic stroke in carbamyl phosphate synthetase deficiency. *Neuropediatrics.* 1997;28(4):229-234.
53. Wiltshire EJ, Poplawski NK, Harbord MG, Harrison RJ, Fletcher JM. Ornithine carbamoyltransferase deficiency presenting with chorea in a female. *J Inherit Metab Dis.* 2000;23(8): 843-844.
54. Scheuerle AE, McVie R, Beaudet AL, Shapira SK. Arginase deficiency presenting as cerebral palsy. *Pediatrics.* 1993;91(5): 995-996.
55. Singh RH, Rhead WJ, Smith W, Lee B, Sniderman King L, Summar M. Nutritional management of urea cycle disorders. *Crit Care Clin.* 2005;21(4 suppl):S27-S35.
56. Snebold NG, Rizzo JF 3rd, Lessell S, Pruett RC. Transient visual loss in ornithine transcarbamoylase deficiency. *Am J Ophthalmol.* 1987;104(4):407-412.
57. Anderson JM, Brodsky MC. Protracted cortical visual loss in a child with ornithine transcarbamylase deficiency. *J Neuro-ophthalmol.* 2010;30(1):99-101.
58. Gorker I, Tuzun U. Autistic-like findings associated with a urea cycle disorder in a 4-year-old girl. *J Psychiatry Neurosci.* 2005; 30(2):133-135.
59. Sedel F, Baumann N, Turpin JC, Lyon-Caen O, Saudubray JM, Cohen D. Psychiatric manifestations revealing inborn errors of metabolism in adolescents and adults. *J Inherit Metab Dis.* 2007; 30(5):631-641.
60. Kleijer WJ, Garritsen VH, Linnebank M, et al. Clinical, enzymatic, and molecular genetic characterization of a biochemical variant type of argininosuccinic aciduria: prenatal and postnatal diagnosis in five unrelated families. *J Inherit Metab Dis.* 2002;25 (5):399-410.
61. Pascual JC, Matarredona J, Mut J. Acrodermatitis enteropathica like dermatosis associated with ornithine transcarbamylase deficiency. *Pediatr Dermatol.* 2007;24(4):394-396.
62. Gyato K, Wray J, Huang ZJ, Yudkoff M, Batshaw ML. Metabolic and neuropsychological phenotype in women heterozygous for ornithine transcarbamylase deficiency. *Ann Neurol.* 2004;55 (1):80-86.
63. Enns GM, O'Brien WE, Kobayashi K, Shinzawa H, Pellegrino JE. Postpartum "psychosis" in mild argininosuccinate synthetase deficiency. *Obstet Gynecol.* 2005;105(5 Pt 2):1244-1246.
64. Häberle J, Vilaseca MA, Meli C, et al. First manifestation of citrullinemia type I as differential diagnosis to postpartum psychosis in the puerperal period. *Eur J Obstet Gynecol Reprod Biol.* 2010;149(2):228-229.

65. Fassier T, Guffon N, Acquaviva C, D'Amato T, Durand DV, Domenech P. Misdiagnosed postpartum psychosis revealing a late-onset urea cycle disorder. *Am J Psychiatry*. 2011;168(6): 576-580.
66. Ahrens MJ, Berry SA, Whitley CB, Markowitz DJ, Plante RJ, Tuchman M. Clinical and biochemical heterogeneity in females of a large pedigree with ornithine transcarbamylase deficiency due to the R141Q mutation. *Am J Med Genet*. 1996;66(3): 311-315.
67. Ausems MG, Bakker E, Berger R, et al. Asymptomatic and late-onset ornithine transcarbamylase deficiency caused by a A208T mutation: clinical, biochemical and DNA analyses in a four-generation family. *Am J Med Genet*. 1997;68(2):236-239.
68. Klaus V, Vermeulen T, Minassian B, et al. Highly variable clinical phenotype of carbamylphosphate synthetase 1 deficiency in one family: an effect of allelic variation in gene expression? *Clin Genet*. 2009;76(3):263-269.
69. Vergano SA, Crossette JM, Cusick FC, Desai BR, Deardorff MA, Sondheimer N. Improving surveillance for hyperammonemia in the newborn. *Mol Genet Metab*. 2013;110 (1–2):102-105.
70. Martin-Hernandez E, Aldamiz-Echevarria L, Castejon-Ponce E, et al. Urea cycle disorders in Spain: an observational, cross-sectional and multicentric study of 104 cases. *Orphanet J Rare Dis*. 2014;9:187.
71. Barsotti RJ. Measurement of ammonia in blood. *J Pediatr*. 2001; 138(1 suppl):S11-S19;discussion S19-20.
72. Häberle J. Clinical practice: the management of hyperammonemia. *Eur J Pediatr*. 2011;170(1):21-34.
73. Marin-Valencia I, Vilaseca MA, Thio M, Garcia-Cazorla A, Artuch R, Campistol J. Assessment of the perimortem protocol in neonates for the diagnosis of inborn errors of metabolism. *Eur J Paediatr Neurol*. 2010;14(2):125-130.
74. Burton BK. Inborn errors of metabolism in infancy: a guide to diagnosis. *Pediatrics*. 1998;102(6):E69.
75. Leonard JV, Morris AA. Diagnosis and early management of inborn errors of metabolism presenting around the time of birth. *Acta Paediatr*. 2006;95(1):6-14.
76. Ellaway CJ, Wilcken B, Christodoulou J. Clinical approach to inborn errors of metabolism presenting in the newborn period. *J Paediatr Child Health*. 2002;38(5):511-517.
77. Saudubray JM, Sedel F, Walter JH. Clinical approach to treatable inborn metabolic diseases: an introduction. *J Inher Metab Dis*. 2006;29(2–3):261-274.
78. Clay AS, Hainline BE. Hyperammonemia in the ICU. *Chest*. 2007;132(4):1368-1378.
79. Häberle J. Clinical and biochemical aspects of primary and secondary hyperammonemic disorders. *Arch Biochem Biophys*. 2013;536(2):101-108.
80. Hudak ML, Jones MD Jr, Brusilow SW. Differentiation of transient hyperammonemia of the newborn and urea cycle enzyme defects by clinical presentation. *J Pediatr*. 1985;107(5):712-719.
81. Tuchman M, Georgieff MK. Transient hyperammonemia of the newborn: a vascular complication of prematurity? *J Perinatol*. 1992;12(3):234-236.
82. Ballard RA, Vinocur B, Reynolds JW, et al. Transient hyperammonemia of the preterm infant. *N Engl J Med*. 1978;299 (17):920-925.
83. Bachmann C. Inherited hyperammonemias. In: Blau N, Duran M, Blaskovic ME, Gibson KM, eds. *Physician's Guide to the Laboratory Diagnosis of Metabolic Diseases*. Berlin, Germany: Springer; 2003:261-276.
84. Summar ML, Barr F, Dawling S, et al. Unmasked adult onset urea cycle disorders in the critical care setting. *Crit Care Clin*. 2005;21(4 suppl):S1-S8.
85. Felig DM, Brusilow SW, Boyer JL. Hyperammonemic coma due to parenteral nutrition in a woman with heterozygous ornithine transcarbamylase deficiency. *Gastroenterology*. 1995;109(1): 282-284.
86. Trivedi M, Zafar S, Spalding MJ, Jonnalagadda S. Ornithine transcarbamylase deficiency unmasked because of gastrointestinal bleeding. *J Clin Gastroenterol*. 2001;32(4):340-343.
87. Summar ML, Dobbelaere D, Brusilow S, Lee B. Diagnosis, symptoms, frequency and mortality of 260 patients with urea cycle disorders from a 21 year, multicentre study of acute hyperammonemic episodes. *Acta Paediatr*. 2008;97(10):1420-1425.
88. Jensen V. The TURP syndrome. *Can J Anaesth*. 1991;38(1):90-96.

89. Kenzaka T, Kato K, Kitao A, et al. Hyperammonemia in urinary tract infections. *PLoS One*. 2015;10(8):e0136220.
90. Hsu KH, Cheng CH, Tseng MH, Hsu JF, Lien R, Yang PH. Hyperammonemia in distal renal tubular acidosis: a new case and review of the literature. *Pediatr Neonatol*. 2015;56(6):432-434.
91. Brusilow SW, Maestri NE. Urea cycle disorders: diagnosis, pathophysiology, and therapy. *Adv Pediatr Infect Dis*. 1996;43: 127-170.
92. Ahrens M, Barsotti R, Batshaw M, et al. Consensus statement from a conference for the management of patients with urea cycle disorders. *J Pediatr*. 2001;138:S1-S5.
93. Summar M, Tuchman M. Proceedings of a consensus conference for the management of patients with urea cycle disorders. *J Pediatr*. 2001;138(1 suppl):S6-S10.
94. Summar M. Current strategies for the management of neonatal urea cycle disorders. *J Pediatr*. 2001;138(1 suppl):S30-S39.
95. Tomlinson S, Westall RG. Argininosuccinic aciduria. Argininosuccinase and arginase in human blood cells. *Clin Sci*. 1964;26:261-269.
96. Yamaguchi S, Brailey LL, Morizono H, Bale AE, Tuchman M. Mutations and polymorphisms in the human ornithine transcarbamylase (OTC) gene. *Hum Mutat*. 2006;27(7):626-632.
97. Cohen YH, Bargal R, Zeigler M, Markus-Eidlitz T, Zuri V, Zeharia A. Hyperargininemia: a family with a novel mutation in an unexpected site. *JIMD Rep*. 2012;5:83-88.
98. Engel K, Nuoffer JM, Muhlhausen C, et al. Analysis of mRNA transcripts improves the success rate of molecular genetic testing in OTC deficiency. *Mol Genet Metab*. 2008;94(3):292-297.
99. Shchelochkov OA, Li FY, Geraghty MT, et al. High frequency detection of deletions and variable rearrangements at the ornithine transcarbamylase (OTC) locus by oligonucleotide array CGH. *Mol Genet Metab*. 2009;96(3):97-105.
100. Wang J, Shchelochkov OA, Zhan H, et al. Molecular characterization of CPS1 deletions by array CGH. *Mol Genet Metab*. 2011; 102(1):103-106.
101. Häberle J, Pauli S, Schmidt E, Schulze Eifling B, Berning C, Koch HG. Mild citrullinemia in Caucasians is an allelic variant of argininosuccinate synthetase deficiency (citrullinemia type 1). *Mol Genet Metab*. 2003;80(3):302-306.
102. Gao HZ, Kobayashi K, Tabata A, et al. Identification of 16 novel mutations in the argininosuccinate synthetase gene and genotype-phenotype correlation in 38 classical citrullinemia patients. *Hum Mutat*. 2003;22(1):24-34.
103. Sancho-Vaello E, Marco-Marin C, Gougeard N, et al. Understanding N-acetyl-L-glutamate synthase deficiency: mutational spectrum, impact of clinical mutations on enzyme functionality, and structural considerations. *Hum Mutat*. 2016;37(7):679-694.
104. Ah Mew N, Caldovic L. N-acetylglutamate synthase deficiency: an insight into genetics, epidemiology, pathophysiology, and treatment. *Appl Clin Genet*. 2011;4:127-135.
105. Kretz R, Hu L, Wettstein V, Leiteritz D, Häberle J. Phytohemagglutinin stimulation of lymphocytes improves mutation analysis of carbamoylphosphate synthetase 1. *Mol Genet Metab*. 2012; 106(3):375-378.
106. Rapp B, Häberle J, Linnebank M, et al. Genetic analysis of carbamoylphosphate synthetase I and ornithine transcarbamylase deficiency using fibroblasts. *Eur J Pediatr*. 2001;160(5):283-287.
107. Häberle J, Shchelochkov OA, Wang J, et al. Molecular defects in human carbamoyl phosphate synthetase I: mutational spectrum, diagnostic and protein structure considerations. *Hum Mutat*. 2011;32(6):579-589.
108. Heibel SK, Ah Mew N, Caldovic L, Daikhin Y, Yudkoff M, Tuchman M. N-carbamylglutamate enhancement of ureagenesis leads to discovery of a novel deleterious mutation in a newly defined enhancer of the NAGS gene and to effective therapy. *Hum Mutat*. 2011;32(10):1153-1160.
109. Williams M, Burlina A, Rubert L, et al. N-Acetylglutamate synthase deficiency due to a recurrent sequence variant in the N- acetylglutamate synthase enhancer region. *Sci Rep*. 2018;8(1): 15436.

110. Leonard JV, Ward Platt MP, Morris AA. Hypothesis: proposals for the management of a neonate at risk of hyperammonaemia due to a urea cycle disorder. *Eur J Pediatr.* 2008;167(3):305-309.
111. Maestri NE, Hauser ER, Bartholomew D, Brusilow SW. Prospective treatment of urea cycle disorders. *J Pediatr.* 1991;119(6): 923-928.
112. Sniderman King L, Singh RH, Rhead WJ, Smith W, Lee B, Summar ML. Genetic counseling issues in urea cycle disorders. *Crit Care Clin.* 2005;21(4 suppl):S37-S44.
113. Häberle J, Koch HG. Genetic approach to prenatal diagnosis in urea cycle defects. *Prenat Diagn.* 2004;24(5):378-383.
114. Kamoun P, Fensom AH, Shin YS, et al. Prenatal diagnosis of the urea cycle diseases: a survey of the European cases. *Am J Med Genet.* 1995;55(2):247-250.
115. Chadeaux-Vekemans B, Rabier D, Chabli A, et al. Improving the prenatal diagnosis of citrullinemia using citrulline/ornithine +arginine ratio in amniotic fluid. *Prenat Diagn.* 2002;22(6): 456-458.
116. Mandell R, Packman S, Laframboise R, et al. Use of amniotic fluid amino acids in prenatal testing for argininosuccinic aciduria and citrullinaemia. *Prenat Diagn.* 1996;16(5):419-424.
117. Miller MJ, Soler-Alfonso CR, Grund JE, et al. Improved standards for prenatal diagnosis of citrullinemia. *Mol Genet Metab.* 2014;112(3):205-209.
118. Wilcken B, Haas M, Joy P, et al. Expanded newborn screening: outcome in screened and unscreened patients at age 6 years. *Pediatrics.* 2009;124(2):e241-e248.
119. Posset R, Garcia-Cazorla A, Valayannopoulos V, et al. Age at disease onset and peak ammonium level rather than interven- tional variables predict the neurological outcome in urea cycle disorders. *J Inherit Metab Dis.* 2016;39(5):661-672.
120. Bachmann C. Long-term outcome of patients with urea cycle disorders and the question of neonatal screening. *Eur J Pediatr.* 2003;162(suppl 1):S29-S33.
121. Krivitzy L, Babikian T, Lee HS, Thomas NH, Burk Paull KL, Batshaw ML. Intellectual, adaptive, and behavioral functioning in children with urea cycle disorders. *Pediatr Res.* 2009;66(1): 96-101.
122. Merritt JL 2nd, Brody LL, Pino G, Rinaldo P. Newborn screening for proximal urea cycle disorders: current evidence supporting recommendations for newborn screening. *Mol Genet Metab.* 2018;124(2):109-113.
123. Cavicchi C, Malvagia S, la Marca G, et al. Hypocitrullinemia in expanded newborn screening by LC-MS/MS is not a reliable marker for ornithine transcarbamylase deficiency. *J Pharm Biomed Anal.* 2009;49(5):1292-1295.
124. Naylor EW, Chace DH. Automated tandem mass spectrometry for mass newborn screening for disorders in fatty acid, organic acid, and amino acid metabolism. *J Child Neurol.* 1999;14(suppl 1):S4-S8.
125. Rashed MS. Clinical applications of tandem mass spectrometry: ten years of diagnosis and screening for inherited metabolic diseases. *J Chromatogr B Biomed Sci Appl.* 2001;758(1):27-48.
126. Sander J, Janzen N, Sander S, et al. Neonatal screening for citrullinaemia. *Eur J Pediatr.* 2003;162(6):417-420.
127. Mercimek Mahmutoglu S, Moeslinger D, Häberle J, et al. Long term outcome of patients with argininosuccinate lyase deficiency diagnosed by newborn screening in Austria. *Mol Genet Metab.* 2010;100(1):24-28.
128. Barends M, Pitt J, Morrissy S, Tzanakos N, Boneh A. Biochemical and molecular characteristics of patients with organic acidaemias and urea cycle disorders identified through newborn screening. *Mol Genet Metab.* 2014;113(1-2):46-52.
129. Sokoro AA, Lepage J, Antonishyn N, et al. Diagnosis and high incidence of hyperornithinemia hyperammonemia homocitrullinemia (HHH) syndrome in northern Saskatchewan. *J Inherit Metab Dis.* 2010;33(suppl 3):S275-S281.
130. Enns GM, Berry SA, Berry GT, Rhead WJ, Brusilow SW, Hamosh A. Survival after treatment with phenylacetate and benzoate for urea cycle disorders. *N Engl J Med.* 2007;356(22): 2282-2292.

131. Schaefer F, Straube E, Oh J, Mehls O, Mayatepek E. Dialysis in neonates with inborn errors of metabolism. *Nephrol Dial Transplant*. 1999;14(4):910-918.
132. Nakamura K, Kido J, Mitsubuchi H, Endo F. Diagnosis and treatment of urea cycle disorder in Japan. *Pediatr Int*. 2014;56(4): 506-509.
133. De Bie I, Lemyre E, Lambert M. Favorable long term outcome following severe neonatal hyperammonemic coma in a patient with argininosuccinate synthetase deficiency. *JIMD Rep*. 2011;1: 83-88.
134. Feillet F, Leonard JV. Alternative pathway therapy for urea cycle disorders. *J Inherit Metab Dis*. 1998;21(suppl 1):101-111.
135. Batshaw ML, MacArthur RB, Tuchman M. Alternative pathway therapy for urea cycle disorders: twenty years later. *J Pediatr*. 2001;138(1 suppl):S46-S54; discussion S54-45.
136. Burlina AB, Ogier H, Korall H, Trefz FK. Long term treatment with sodium phenylbutyrate in ornithine transcarbamylase deficient patients. *Mol Genet Metab*. 2001;72(4):351-355.
137. MacArthur RB, Altincatal A, Tuchman M. Pharmacokinetics of sodium phenylacetate and sodium benzoate following intravenous administration as both a bolus and continuous infusion to healthy adult volunteers. *Mol Genet Metab*. 2004;81(suppl 1): S67-S73.
138. Praphanphoj V, Boyadjiev SA, Waber LJ, Brusilow SW, Geraghty MT. Three cases of intravenous sodium benzoate and sodium phenylacetate toxicity occurring in the treatment of acute hyperammonaemia. *J Inherit Metab Dis*. 2000;23(2):129-136.
139. Picca S, Bartuli A, Dionisi Vici C. Medical management and dialysis therapy for the infant with an inborn error of metabolism. *Semin Nephrol*. 2008;28(5):477-480.
140. Sadowski RH, Harmon WE, Jabs K. Acute hemodialysis of infants weighing less than five kilograms. *Kidney Int*. 1994;45 (3):903-906.
141. Tsai IJ, Hwu WL, Huang SC, et al. Efficacy and safety of intermittent hemodialysis in infants and young children with inborn errors of metabolism. *Pediatr Nephrol*. 2014;29(1):111-116.
142. Hiroma T, Nakamura T, Tamura M, Kaneko T, Komiyama A. Continuous venovenous hemodiafiltration in neonatal onset hyperammonemia. *Am J Perinatol*. 2002;19(4):221-224.
143. Spinale JM, Laskin BL, Sondheimer N, Swartz SJ, Goldstein SL. High-dose continuous renal replacement therapy for neonatal hyperammonemia. *Pediatr Nephrol*. 2013;28(6):983-986.
144. Boneh A. Dietary protein in urea cycle defects: how much? Which? How? *Mol Genet Metab*. 2014;113(1-2):109-112.
145. Rodney S, Boneh A. Amino acid profiles in patients with urea cycle disorders at admission to hospital due to metabolic decompensation. *JIMD Rep*. 2013;9:97-104.
146. WHO Technical Report Series. Protein and amino acid requirement in human Nutrition; 2007.
147. Shchelochkov OA, Dickinson K, Scharschmidt BF, Lee B, Marino M, Le Mons C. Barriers to drug adherence in the treatment of urea cycle disorders: assessment of patient, caregiver and provider perspectives. *Mol Genet Metab Rep*. 2016;8:43-47.
148. Berry GT, Steiner RD. Long term management of patients with urea cycle disorders. *J Pediatr*. 2001;138(1 suppl):S56-S60. discussion S60-51.
149. Dixon M. Disorders of amino acid metabolism, organic acidemias and urea cycle defects. Organic acidemias and urea cycle disorders. In: Shaw V, Lawson M, eds., Wiley & Sons Ltd, Oxford, UK. *Clinical Pediatric Dietetics*; 2007:357-389.
150. Leonard JV. The nutritional management of urea cycle disorders. *J Pediatr*. 2001;138(1 suppl):S40-S44;discussion S44-45.
151. Adam S, Almeida MF, Assoun M, et al. Dietary management of urea cycle disorders: European practice. *Mol Genet Metab*. 2013; 110(4):439-445.
152. Adam S, Champion H, Daly A, et al. Dietary management of urea cycle disorders: UK practice. *J Hum Nutr Diet*. 2012;25(4): 398-404.
153. Scaglia F, Carter S, O'Brien WE, Lee B. Effect of alternative pathway therapy on branched chain amino acid metabolism in urea cycle disorder patients. *Mol Genet Metab*. 2004;81(suppl 1): S79-S85.

154. Burrage LC, Jain M, Gandolfo L, Lee BH, Members of the Urea Cycle Disorders Consortium, Nagamani SC. Sodium phenylbutyrate decreases plasma branched chain amino acids in patients with urea cycle disorders. *Mol Genet Metab.* 2014;113 (1–2):131-135.
155. Scaglia F. New insights in nutritional management and amino acid supplementation in urea cycle disorders. *Mol Genet Metab.* 2010;100(suppl 1):S72-S76.
156. Bachmann C. Hyperammonaemia: review of current treatment strategies. In: Bachmann C, Häberle J, Leonard JV, eds. *Pathophysiology and management of hyperammonemia.* Heilbronn, Germany: SPS Publications; 2006:157-173.
157. Vlaardingerbroek H, Hornstra G, de Koning TJ, et al. Essential polyunsaturated fatty acids in plasma and erythrocytes of children with inborn errors of amino acid metabolism. *Mol Genet Metab.* 2006;88(2):159-165.
158. Sanjurjo P, Ruiz JI, Montejo M. Inborn errors of metabolism with a protein restricted diet: effect on polyunsaturated fatty acids. *J Inher Metab Dis.* 1997;20(6):783-789.
159. Mendez-Figueroa H, Lamance K, Sutton VR, Aagaard-Tillery K, Van den Veyver I. Management of ornithine transcarbamylase deficiency in pregnancy. *Am J Perinatol.* 2010;27(10):775-784.
160. Worthington S, Christodoulou J, Wilcken B, Peat B. Pregnancy and argininosuccinic aciduria. *J Inher Metab Dis.* 1996;19(5): 621-623.
161. Ituk U, Constantinescu OC, Allen TK, Small MJ, Habib AS. Peripartum management of two parturients with ornithine trans- carbamylase deficiency. *Int J Obstet Anesth.* 2012;21(1):90-93.
162. Langendonk JG, Roos JC, Angus L, et al. A series of pregnancies in women with inherited metabolic disease. *J Inher Metab Dis.* 2012;35(3):419-424.
163. Kim SZ, Song WJ, Nyhan WL, Ficicioglu C, Mandell R, Shih VE. Long-term follow-up of four patients affected by HHH syndrome. *Clin Chim Acta.* 2012;413(13–14):1151-1155.
164. Singh RH. Nutrition management of patients with inherited disorders of urea cycle enzymes. In: Acosta PB, ed. *Nutrition management of patients with inherited metabolic disorders.* Sudbury: Jones & Bartlett Learning; 2009:405-429.
165. Wilcken B. Problems in the management of urea cycle disorders. *Mol Genet Metab.* 2004;81(suppl 1):S86-S91.
166. Maestri NE, Brusilow SW, Clissold DB, Bassett SS. Long-term treatment of girls with ornithine transcarbamylase deficiency. *N Engl J Med.* 1996;335(12):855-859.
167. Comte B, Kasumov T, Pierce BA, et al. Identification of phenylbutyrylglutamine, a new metabolite of phenylbutyrate metabolism in humans. *J Mass Spectrom.* 2002;37(6):581-590.
168. Guffon N, Kibleur Y, Copalu W, Tissen C, Breitreutz J. Developing a new formulation of sodium phenylbutyrate. *Arch Dis Child.* 2012;97(12):1081-1085.
169. Kibleur Y, Dobbelaere D, Barth M, Brassier A, Guffon N. Results from a Nationwide cohort temporary utilization authorization (ATU) survey of patients in France treated with Pheburane ((R)) (sodium phenylbutyrate) taste masked granules. *Paediatr Drugs.* 2014;16(5):407-415.
170. Lichter Konecki U, Diaz GA, Merritt JL 2nd, et al. Ammonia control in children with urea cycle disorders (UCDs); phase 2 comparison of sodium phenylbutyrate and glycerol phenylbutyrate. *Mol Genet Metab.* 2011;103(4):323-329.
171. Berry SA, Lichter Konecki U, Diaz GA, et al. Glycerol phenylbutyrate treatment in children with urea cycle disorders: pooled analysis of short and long term ammonia control and outcomes. *Mol Genet Metab.* 2014;112(1):17-24.
172. Diaz GA, Krivitzky LS, Mokhtarani M, et al. Ammonia control and neurocognitive outcome among urea cycle disorder patients treated with glycerol phenylbutyrate. *Hepatology.* 2013;57(6): 2171-2179.
173. Mokhtarani M, Diaz GA, Rhead W, et al. Urinary phenylacetylglutamine as dosing biomarker for patients with urea cycle disorders. *Mol Genet Metab.* 2012;107(3):308-314.

174. Smith W, Diaz GA, Lichter Konecki U, et al. Ammonia control in children ages 2 months through 5 years with urea cycle disorders: comparison of sodium phenylbutyrate and glycerol phenylbutyrate. *J Pediatr*. 2013;162(6):1228-1234, 1234.e1.
175. Mokhtarani M, Diaz GA, Rhead W, et al. Elevated phenylacetic acid levels do not correlate with adverse events in patients with urea cycle disorders or hepatic encephalopathy and can be predicted based on the plasma PAA to PAGN ratio. *Mol Genet Metab*. 2013;110(4):446-453.
176. Tremblay GC, Qureshi IA. The biochemistry and toxicology of benzoic acid metabolism and its relationship to the elimination of waste nitrogen. *Pharmacol Ther*. 1993;60(1):63-90.
177. Griffith AD, Cyr DM, Egan SG, Tremblay GC. Inhibition of pyruvate carboxylase by sequestration of coenzyme A with sodium benzoate. *Arch Biochem Biophys*. 1989;269(1):201-207.
178. Monneret C. Histone deacetylase inhibitors. *Eur J Med Chem*. 2005;40(1):1-13.
179. Tuchman M, Lee B, Lichter Konecki U, et al. Cross sectional multicenter study of patients with urea cycle disorders in the United States. *Mol Genet Metab*. 2008;94(4):397-402.
180. Lamb S, Aye CY, Murphy E, Mackillop L. Multidisciplinary management of ornithine transcarbamylase (OTC) deficiency in pregnancy: essential to prevent hyperammonemic complications. *BMJ Case Rep*. 2013; Jan 2;2013:bcr2012007416
181. Brusilow SW, Batshaw ML. Arginine therapy of argininosuccinase deficiency. *Lancet*. 1979;1(8108):124-127.
182. Brusilow SW. Arginine, an indispensable amino acid for patients with inborn errors of urea synthesis. *J Clin Invest*. 1984;74(6): 2144-2148.
183. Nagasaka H, Yorifuji T, Murayama K, et al. Effects of arginine treatment on nutrition, growth and urea cycle function in seven Japanese boys with late onset ornithine transcarbamylase deficiency. *Eur J Pediatr*. 2006;165(9):618-624.
184. Keskinen P, Siitonen A, Salo M. Hereditary urea cycle diseases in Finland. *Acta Paediatr*. 2008;97(10):1412-1419.
185. Kim S, Paik WK, Cohen PP. Ammonia intoxication in rats: protection by N-carbamoyl-L-glutamate plus L-arginine. *Proc Natl Acad Sci USA*. 1972;69(12):3530-3533.
186. Caldovic L, Morizono H, Daikhin Y, et al. Restoration of ureagenesis in N-acetylglutamate synthase deficiency by N- carbamylglutamate. *J Pediatr*. 2004;145(4):552-554.
187. Bachmann C, Colombo JP, Jaggi K. N-acetylglutamate synthetase (NAGS) deficiency: diagnosis, clinical observations and treatment. *Adv Exp Med Biol*. 1982;153:39-45.
188. Guffon N, Schiff M, Cheillan D, Wermuth B, Häberle J, Vianey-Saban C. Neonatal hyperammonemia: the N-carbamoyl-L- glutamic acid test. *J Pediatr*. 2005;147(2):260-262.
189. Tuchman M, Caldovic L, Daikhin Y, et al. N-carbamylglutamate markedly enhances ureagenesis in N-acetylglutamate deficiency and propionic acidemia as measured by isotopic incorporation and blood biomarkers. *Pediatr Res*. 2008;64(2):213-217.
190. Häberle J. Role of carglumic acid in the treatment of acute hyperammonemia due to N-acetylglutamate synthase deficiency. *Ther Clin Risk Manag*. 2011;7:1-6.
191. Häberle J. Carglumic acid for the treatment of N-acetylglutamate synthase deficiency and of acute hyperammonemia. *Expert Rev Endocrinol Metab*. 2012;7:263-271.
192. Feoli-Fonseca JC, Lambert M, Mitchell G, et al. Chronic sodium benzoate therapy in children with inborn errors of urea synthesis: effect on carnitine metabolism and ammonia nitrogen removal. *Biochem Mol Med*. 1996;57(1):31-36.
193. Mayatepek E, Kurczynski TW, Hoppel CL, Gunning WT. Carnitine deficiency associated with ornithine transcarbamylase deficiency. *Pediatr Neurol*. 1991;7(3):196-199.
194. Ohtani Y, Ohyanagi K, Yamamoto S, Matsuda I. Secondary carnitine deficiency in hyperammonemic attacks of ornithine transcarbamylase deficiency. *J Pediatr*. 1988;112(3):409-414.
195. Häberle J, Lachman R. Diagnosis and treatment of OTC in females. Paper presented at: EMG Workshop Proceedings 2010; Lisboa.

196. Morgan TM, Schlegel C, Edwards KM, et al. Vaccines are not associated with metabolic events in children with urea cycle disorders. *Pediatrics*. 2011;127(5):e1147-e1153.
197. Schmidt J, Kroeber S, Irouschek A, Birkholz T, Schroth M, Albrecht S. Anesthetic management of patients with ornithine transcarbamylase deficiency. *Paediatr Anaesth*. 2006;16(3): 333-337.
198. Whittington PF, Alonso EM, Boyle JT, et al. Liver transplantation for the treatment of urea cycle disorders. *J Inherit Metab Dis*. 1998;21(suppl 1):112-118.
199. Kim IK, Niemi AK, Krueger C, et al. Liver transplantation for urea cycle disorders in pediatric patients: a single center experience. *Pediatr Transplant*. 2013;17(2):158-167.
200. Leonard JV, McKiernan PJ. The role of liver transplantation in urea cycle disorders. *Mol Genet Metab*. 2004;81(suppl 1): S74-S78.
201. Morioka D, Kasahara M, Takada Y, et al. Current role of liver transplantation for the treatment of urea cycle disorders: a review of the worldwide English literature and 13 cases at Kyoto University. *Liver Transpl*. 2005;11(11):1332-1342.
202. Campeau PM, Pivalizza PJ, Miller G, et al. Early orthotopic liver transplantation in urea cycle defects: follow up of a developmental outcome study. *Mol Genet Metab*. 2010;100(suppl 1): S84-S87.
203. Bucuvalas JC, Britto M, Krug S, et al. Health related quality of life in pediatric liver transplant recipients: a single center study. *Liver Transpl*. 2003;9(1):62-71.
204. Alonso EM, Neighbors K, Mattson C, et al. Functional outcomes of pediatric liver transplantation. *J Pediatr Gastroenterol Nutr*. 2003;37(2):155-160.
205. Yu L, Rayhill SC, Hsu EK, Landis CS. Liver transplantation for urea cycle disorders: analysis of the united network for organ sharing database. *Transplant Proc*. 2015;47(8):2413-2418.
206. Bourdeaux C, Darwish A, Jamart J, et al. Living-related versus deceased donor pediatric liver transplantation: a multivariate analysis of technical and immunological complications in 235 recipients. *Am J Transplant*. 2007;7(2):440-447.
207. Kawagishi N, Satoh K, Enomoto Y, et al. Improved quality of life and unchanged magnetic resonance brain imaging after living donor liver transplantation for late onset ornithine transcarbamylase deficiency: report of a case. *Surg Today*. 2005;35 (12):1087-1091.
208. Busuttil AA, Goss JA, Seu P, et al. The role of orthotopic liver transplantation in the treatment of ornithine transcarbamylase deficiency. *Liver Transpl Surg*. 1998;4(5):350-354.
209. Fletcher JM, Couper R, Moore D, Coxon R, Dorney S. Liver transplantation for citrullinaemia improves intellectual function. *J Inherit Metab Dis*. 1999;22(5):581-586.
210. Santos Silva E, Martins E, Cardoso ML, Barbot C, Vilarinho L, Medina M. Liver transplantation in a case of argininaemia. *J Inherit Metab Dis*. 2001;24(8):885-887.
211. Ensenaer R, Tuchman M, El-Youssef M, et al. Management and outcome of neonatal-onset ornithine transcarbamylase deficiency following liver transplantation at 60 days of life. *Mol Genet Metab*. 2005;84(4):363-366.
212. McBride KL, Miller G, Carter S, Karpen S, Goss J, Lee B. Developmental outcomes with early orthotopic liver transplantation for infants with neonatal onset urea cycle defects and a female patient with late onset ornithine transcarbamylase deficiency. *Pediatrics*. 2004;114(4):e523-e526.
213. Newnham T, Hardikar W, Allen K, et al. Liver transplantation for argininosuccinic aciduria: clinical, biochemical, and meta- bolic outcome. *Liver Transpl*. 2008;14(1):41-45.
214. Stevenson T, Millan MT, Wayman K, et al. Long-term outcome following pediatric liver transplantation for metabolic disorders. *Pediatr Transplant*. 2010;14(2):268-275.
215. Perito ER, Rhee S, Roberts JP, Rosenthal P. Pediatric liver transplantation for urea cycle disorders and organic acidemias: united network for organ sharing data for 2002-2012. *Liver Transpl*. 2014;20(1):89-99.
216. Rabier D, Narcy C, Bardet J, Parvy P, Saudubray JM, Kamoun P. Arginine remains an essential amino acid after liver transplantation in urea cycle enzyme deficiencies. *J Inherit Metab Dis*. 1991;14(3):277-280.

217. Sundaram SS, Alonso EM, Whittington PF. Liver transplantation in neonates. *Liver Transpl.* 2003;9(8):783-788.
218. Hashikura Y, Ichida T, Umeshita K, et al. Donor complications associated with living donor liver transplantation in Japan. *Transplantation.* 2009;88(1):110-114.
219. Nagasaka H, Yorifuji T, Egawa H, Kikuta H, Tanaka K, Kobayashi K. Successful living-donor liver transplantation from an asymptomatic carrier mother in ornithine transcarbamylase deficiency. *J Pediatr.* 2001;138(3):432-434.
220. Morioka D, Takada Y, Kasahara M, et al. Living donor liver transplantation for noncirrhotic inheritable metabolic liver diseases: impact of the use of heterozygous donors. *Transplantation.* 2005;80(5):623-628.
221. Kasahara M, Sakamoto S, Horikawa R, et al. Living donor liver transplantation for pediatric patients with metabolic disorders: the Japanese multicenter registry. *Pediatr Transplant.* 2014;18(1): 6-15.
222. Wakiya T, Sanada Y, Mizuta K, et al. Living donor liver transplantation for ornithine transcarbamylase deficiency. *Pediatr Transplant.* 2011;15(4):390-395.
223. Lee B, Diaz GA, Rhead W, et al. Blood ammonia and glutamine as predictors of hyperammonemic crises in patients with urea cycle disorder. *Genet Med.* 2015;17(7):561-568.
224. Bachmann C. Preanalytical effects on biochemical results for medical decisions in urea cycle defects. *J Pediatr Biochem.* 2014; 4(1):17-22.
225. Maestri NE, McGowan KD, Brusilow SW. Plasma glutamine concentration: a guide in the management of urea cycle disorders. *J Pediatr.* 1992;121(2):259-261.
226. Brusilow SW. Phenylacetylglutamine may replace urea as a vehicle for waste nitrogen excretion. *Pediatr Res.* 1991;29(2): 147-150.
227. Bachmann C. Interpretation of plasma amino acids in the follow up of patients: the impact of compartmentation. *J Inherit Metab Dis.* 2008;31(1):7-20.
228. Duran M. Amino acids. In: Blau N, Duran M, Gibson KM, eds. *Laboratory Guide to the Methods in Biochemical Genetics.* Springer, Heidelberg; 2008:53-89.
229. Boenzi S, Pastore A, Martinelli D, et al. Creatine metabolism in urea cycle defects. *J Inherit Metab Dis.* 2012;35(4):647-653.
230. Arias A, Garcia-Villoria J, Ribes A. Guanidinoacetate and creatine/creatinine levels in controls and patients with urea cycle defects. *Mol Genet Metab.* 2004;82(3):220-223.
231. Bireley WR, Van Hove JL, Gallagher RC, Fenton LZ. Urea cycle disorders: brain MRI and neurological outcome. *Pediatr Radiol.* 2012;42(4):455-462.
232. Gropman A. Brain imaging in urea cycle disorders. *Mol Genet Metab.* 2010;100(suppl 1):S20-S30.
233. Gunz AC, Choong K, Potter M, Miller E. Magnetic resonance imaging findings and neurodevelopmental outcomes in neonates with urea cycle defects. *Int Med Case Rep J.* 2013;6:41-48.
234. Gropman AL, Fricke ST, Seltzer RR, et al. 1H MRS identifies symptomatic and asymptomatic subjects with partial ornithine transcarbamylase deficiency. *Mol Genet Metab.* 2008;95(1-2): 21-30.
235. Gropman AL, Gertz B, Shattuck K, et al. Diffusion tensor imaging detects areas of abnormal white matter microstructure in patients with partial ornithine transcarbamylase deficiency. *AJNR Am J Neuroradiol.* 2010;31(9):1719-1723.
236. Takanashi J, Barkovich AJ, Cheng SF, et al. Brain MR imaging in neonatal hyperammonemic encephalopathy resulting from proximal urea cycle disorders. *AJNR Am J Neuroradiol.* 2003;24(6):1184-1187.
237. Majoie CB, Mourmans JM, Akkerman EM, Duran M, Poll-The BT. Neonatal citrullinemia: comparison of conventional MR, diffusion-weighted, and diffusion tensor findings. *AJNR Am J Neuroradiol.* 2004;25(1):32-35.
238. Connelly A, Cross JH, Gadian DG, Hunter JV, Kirkham FJ, Leonard JV. Magnetic resonance spectroscopy shows increased brain glutamine in ornithine carbamoyl transferase deficiency. *Pediatr Res.* 1993;33(1):77-81.

239. Choi CG, Yoo HW. Localized proton MR spectroscopy in infants with urea cycle defect. *AJNR Am J Neuroradiol*. 2001;22(5): 834-837.
240. Gropman AL, Shattuck K, Prust MJ, et al. Altered neural activation in ornithine transcarbamylase deficiency during executive cognition: an fMRI study. *Hum Brain Mapp*. 2013;34(4): 753-761.
241. Drogari E, Leonard JV. Late onset ornithine carbamoyl transferase deficiency in males. *Arch Dis Child*. 1988;63(11):1363-1367.
242. Jamiolkowski D, Kolker S, Glahn EM, et al. Behavioural and emotional problems, intellectual impairment and health-related quality of life in patients with organic acidurias and urea cycle disorders. *J Inherit Metab Dis*. 2016;39(2):231-241.
243. Zeltner NA, Huemer M, Baumgartner MR, Landolt MA. Quality of life, psychological adjustment, and adaptive functioning of patients with intoxication-type inborn errors of metabolism a systematic review. *Orphanet J Rare Dis*. 2014;9:159.
244. Hatzmann J, Heymans HS, Ferreri-Carbonell A, van Praag BM, Grootenhuis MA. Hidden consequences of success in pediatrics: parental health related quality of life results from the care project. *Pediatrics*. 2008;122(5):e1030-e1038.
245. Cederbaum JA, LeMons C, Rosen M, Ahrens M, Vonachen S, Cederbaum SD. Psychosocial issues and coping strategies in families affected by urea cycle disorders. *J Pediatr*. 2001;138(1 suppl):S72-S80.
246. Fabre A, Baumstarck K, Cano A, et al. Assessment of quality of life of the children and parents affected by inborn errors of metabolism with restricted diet: preliminary results of a cross sectional study. *Health Qual Life Outcomes*. 2013;11:158.
247. Zeltner NA, Landolt MA, Baumgartner MR, et al. Living with intoxication type inborn errors of metabolism: a qualitative analysis of interviews with paediatric patients and their parents. *JIMD Rep*. 2017;31:1-9.
248. Zeltner NA, Baumgartner MR, Bondarenko A, et al. Development and psychometric evaluation of the MetabQoL 1.0: a quality of life questionnaire for paediatric patients with intoxication type inborn errors of metabolism. *JIMD Rep*. 2017;37:27-35.
249. Feillet F, MacDonald A, Hartung Perron D, Burton B. Outcomes beyond phenylalanine: an international perspective. *Mol Genet Metab*. 2010;99(suppl 1):S79-S85.
250. Rokicki D, Pajdowska M, Trubicka J, et al. 3-Methylglutaconic aciduria, a frequent but underrecognized finding in carbamoyl phosphate synthetase I deficiency. *Clin Chim Acta*. 2017;471: 95-100.
251. Nordenstrom A, Halldin M, Hallberg B, Alm J. A trial with N-carbamylglutamate may not detect all patients with NAGS deficiency and neonatal onset. *J Inherit Metab Dis*. 2007;30(3):400.
252. Ah Mew N, Daikhin E, Payan I, et al. N-carbamylglutamate increases ureagenesis in patients with CPSI deficiency (abstract). *Mol Genet Metab*. 2010;99:207.
253. Williams M, Huijman JG, van Diggelen OP, van der Louw EJTM, De Klerk JBC, Häberle J. Carbamoylphosphate synthase I (CPS 1) deficiency: treatment with carglumic acid (Carbaglu) (abstract). *J Inherit Metab Dis*. 2010;33:S118.
254. Caldovic L, Morizono H, Tuchman M. Mutations and polymorphisms in the human N-acetylglutamate synthase (NAGS) gene. *Hum Mutat*. 2007;28(8):754-759.
255. Heckmann M, Wermuth B, Häberle J, Koch HG, Gortner L, Kreuder JG. Misleading diagnosis of partial N-acetylglutamate synthase deficiency based on enzyme measurement corrected by mutation analysis. *Acta Paediatr*. 2005;94(1):121-124.
256. Caldovic L, Morizono H, Panglao MG, Cheng SF, Packman S, Tuchman M. Null mutations in the N-acetylglutamate synthase gene associated with acute neonatal disease and hyperammonemia. *Hum Genet*. 2003;112(4):364-368.
257. Caldovic L, Morizono H, Panglao MG, et al. Late onset N- acetylglutamate synthase deficiency caused by hypomorphic alleles. *Hum Mutat*. 2005;25(3):293-298.

258. Ihara K, Miyako K, Ishimura M, et al. A case of hyperinsulinism/hyperammonaemia syndrome with reduced carbamoyl-phosphate synthetase-1 activity in liver: a pitfall in enzymatic diagnosis for hyperammonaemia. *J Inherit Metab Dis*. 2005;28(5):681-687.
259. Gautschi M, Eggimann S, Nuoffer JM. Current role of enzyme analysis for urea cycle disorders. *J Pediatr Biochem*. 2014;4(1): 23-32.
260. Gessler P, Buchal P, Schwenk HU, Wermuth B. Favourable long term outcome after immediate treatment of neonatal hyperammonemia due to N-acetylglutamate synthase deficiency. *Eur J Pediatr*. 2010;169(2):197-199.
261. Belanger-Quintana A, Martinez-Pardo M, Garcia MJ, et al. Hyperammonaemia as a cause of psychosis in an adolescent. *Eur J Pediatr*. 2003;162(11):773-775.
262. Guffon N, Gessler P, Galloway P, et al. Treatment of NAGS deficiency: retrospective data on 23 patients treated with carglumic acid over 16 years (abstract). *Mol Genet Metab*. 2011;102(3): 286-287.
263. Daniotti M, la Marca G, Fiorini P, Filippi L. New developments in the treatment of hyperammonemia: emerging use of carglumic acid. *Int J Gen Med*. 2011;4:21-28.
264. Ah Mew N, McCarter R, Daikhin Y, et al. Augmenting ureagenesis in patients with partial carbamyl phosphate synthetase 1 deficiency with N-carbamyl-L-glutamate. *J Pediatr*. 2014; 165(2):401-403.e403.
265. Ihara K, Yoshino M, Hoshina T, et al. Coagulopathy in patients with late onset ornithine transcarbamylase deficiency in remission state: a previously unrecognized complication. *Pediatrics*. 2013;131(1):e327-e330.
266. Prada CE, Kaul A, Hopkin RJ, et al. Recurrent pancreatitis in ornithine transcarbamylase deficiency. *Mol Genet Metab*. 2012; 106(4):482-484.
267. Tuchman M. The clinical, biochemical, and molecular spectrum of ornithine transcarbamylase deficiency. *J Lab Clin Med*. 1992; 120(6):836-850.
268. Numata S, Harada E, Maeno Y, et al. Paternal transmission and slow elimination of mutant alleles associated with late onset ornithine transcarbamylase deficiency in male patients. *J Hum Genet*. 2008;53(1):10-17.
269. Brassier A, Gobin S, Arnoux JB, et al. Long-term outcomes in ornithine transcarbamylase deficiency: a series of 90 patients. *Orphanet J Rare Dis*. 2015;10:58.
270. Caldovic L, Abdikarim I, Narain S, Tuchman M, Morizono H. Genotype phenotype correlations in ornithine transcarbamylase deficiency: a mutation update. *J Genet Genomics*. 2015;42(5): 181-194.
271. Krijt J, Sokolova J, Jesina P, et al. Activity of the liver enzyme ornithine carbamoyltransferase (OTC) in blood: LC-MS/MS assay for non-invasive diagnosis of ornithine carbamoyl transferase deficiency. *Clin Chem Lab Med*. 2017;55(8):1168- 1177.
272. Hauser ER, Finkelstein JE, Valle D, Brusilow SW. Allopurinol induced orotidinuria. A test for mutations at the ornithine carbamoyltransferase locus in women. *N Engl J Med*. 1990;322 (23):1641-1645.
273. Maestri NE, Lord C, Glynn M, Bale A, Brusilow SW. The phenotype of ostensibly healthy women who are carriers for ornithine transcarbamylase deficiency. *Medicine (Baltimore)*. 1998; 77(6):389-397.
274. Grunewald S, Fairbanks L, Genet S, et al. How reliable is the allopurinol load in detecting carriers for ornithine transcarbamylase deficiency? *J Inherit Metab Dis*. 2004;27(2): 179-186.
275. Tuchman M. Allopurinol induced orotidinuria. *N Engl J Med*. 1990;323(19):1352-1353.
276. Burlina AB, Ferrari V, Dionisi-Vici C, Bordugo A, Zacchello F, Tuchman M. Allopurinol challenge test in children. *J Inherit Metab Dis*. 1992;15(5):707-712.
277. Riudor E, Arranz JA, Rodes M, Rubio V, Sentis M, Burlina AB. Influence of dose and age on the response of the allopurinol test for ornithine carbamoyltransferase deficiency in control infants. *J Inherit Metab Dis*. 2000;23(7):662-668.
278. Potter M, Hammond JW, Sim KG, Green AK, Wilcken B. Ornithine carbamoyltransferase deficiency: improved sensitivity of testing for protein tolerance in the diagnosis of heterozygotes. *J Inherit Metab Dis*. 2001;24(1):5-14.

279. de Groot MJ, Cuppen M, Eling M, et al. Metabolic investigations prevent liver transplantation in two young children with citrullinemia type I. *J Inherit Metab Dis*. 2010;33(Suppl3): S413–416.
280. Engel K, Höhne W, Häberle J. Mutations and polymorphisms in the human argininosuccinate synthetase (ASS1) gene. *Hum Mutat*. 2009;30(3):300-307.
281. Kleijer WJ, Thoomes R, Galjaard H, Wendel U, Fowler B. First trimester (chorion biopsy) diagnosis of citrullinaemia and methylmalonicaciduria. *Lancet*. 1984;2(8415):1340.
282. Berning C, Bieger I, Pauli S, et al. Investigation of citrullinemia type I variants by in vitro expression studies. *Hum Mutat*. 2008; 29(10):1222-1227.
283. Engel K, Vuissoz JM, Eggimann S, et al. Bacterial expression of mutant argininosuccinate lyase reveals imperfect correlation of in vitro enzyme activity with clinical phenotype in argininosuccinic aciduria. *J Inherit Metab Dis*. 2012;35(1): 133-140.
284. Trevisson E, Burlina A, Doimo M, et al. Functional complementation in yeast allows molecular characterization of missense argininosuccinate lyase mutations. *J Biol Chem*. 2009;284(42): 28926-28934.
285. Balmer C, Pandey AV, Rüfenacht V, et al. Mutations and polymorphisms in the human Argininosuccinate Lyase (ASL) gene. *Hum Mutat*. 2014;35(1):27-35.
286. Hu L, Pandey AV, Balmer C, et al. Unstable argininosuccinate lyase in variant forms of the urea cycle disorder argininosuccinic aciduria. *J Inherit Metab Dis*. 2015;38(5):815-827.
287. Nagamani SC, Erez A, Lee B. Argininosuccinate lyase deficiency. *Genet Med*. 2012;14(5):501-507.
288. Kölker S, Sauer SW, Surtees RA, Leonard JV. The aetiology of neurological complications of organic acidaemias a role for the blood brain barrier. *J Inherit Metab Dis*. 2006;29(6):701-704. discussion 705-706.
289. van Spronsen FJ, Reijngoud DJ, Verhoeven NM, Soorani-Lunsing RJ, Jakobs C, Sijens PE. High cerebral guanidinoacetate and variable creatine concentrations in argininosuccinate synthetase and lyase deficiency: implications for treatment? *Mol Genet Metab*. 2006;89(3):274-276.
290. Erez A, Nagamani SC, Shchelochkov OA, et al. Requirement of argininosuccinate lyase for systemic nitric oxide production. *Nat Med*. 2011;17(12):1619-1626.
291. Brunetti-Pierri N, Erez A, Shchelochkov O, Craigen W, Lee B. Systemic hypertension in two patients with ASL deficiency: a result of nitric oxide deficiency? *Mol Genet Metab*. 2009;98 (1–2):195-197.
292. Erez A, Nagamani SC, Lee B. Argininosuccinate lyase deficiency argininosuccinic aciduria and beyond. *Am J Med Genet C Semin Med Genet*. 2011;157C(1):45-53.
293. Nagamani SC, Campeau PM, Shchelochkov OA, et al. Nitric oxide supplementation for treatment of long term complications in argininosuccinic aciduria. *Am J Hum Genet*. 2012;90(5): 836-846.
294. Nagamani SC, Shchelochkov OA, Mullins MA, et al. A randomized controlled trial to evaluate the effects of high dose versus low dose of arginine therapy on hepatic function tests in argininosuccinic aciduria. *Mol Genet Metab*. 2012;107(3): 315-321.
295. Schlune A, Vom Dahl S, Haussinger D, Ensenauer R, Mayatepek E. Hyperargininemia due to arginase I deficiency: the original patients and their natural history, and a review of the literature. *Amino Acids*. 2015;47(9):1751-1762.
296. Cederbaum SD, Moedjono SJ, Shaw KN, Carter M, Naylor E, Walzer M. Treatment of hyperargininaemia due to arginase deficiency with a chemically defined diet. *J Inherit Metab Dis*. 1982; 5(2):95-99.
297. Ash DE, Scolnick LR, Kanyo ZF, Vockley JG, Cederbaum SD, Christianson DW. Molecular basis of hyperargininemia: structure function consequences of mutations in human liver arginase. *Mol Genet Metab*. 1998;64(4):243-249.
298. Scaglia F, Lee B. Clinical, biochemical, and molecular spectrum of hyperargininemia due to arginase I deficiency. *Am J Med Genet C Semin Med Genet*. 2006;142C(2):113-120.
299. Diez-Fernandez C, Rüfenacht V, Gemperle C, Fingerhut R, Häberle J. Mutations and common variants in the human arginase 1 (ARG1) gene: impact on patients, diagnostics, and protein structure considerations. *Hum Mutat*. 2018;39(8):1029-1050.

300. Brosnan JT, Brosnan ME. Creatine metabolism and the urea cycle. *Mol Genet Metab.* 2010;100(suppl 1):S49-S52.
301. Huemer M, Carvalho DR, Brum JM, et al. Clinical phenotype, biochemical profile, and treatment in 19 patients with arginase 1 deficiency. *J Inher Metab Dis.* 2016;39(3):331-340.
302. Jain-Ghai S, Nagamani SC, Blaser S, Siriwardena K, Feigenbaum A. Arginase I deficiency: severe infantile presentation with hyperammonemia: more common than reported? *Mol Genet Metab.* 2011;104(1-2):107-111.
303. Scholl-Bürgi S, Sigl SB, Häberle J, et al. Amino acids in CSF and plasma in hyperammonaemic coma due to arginase1 deficiency. *J Inher Metab Dis.* 2008;31(suppl 2):S323-S328.
304. Zhang Y, Landau YE, Miller DT, Marsden D, Berry GT, Kellogg MD. Recurrent unexplained hyperammonemia in an adolescent with arginase deficiency. *Clin Biochem.* 2012;45(18): 1583-1586.
305. Debray FG, Lambert M, Lemieux B, et al. Phenotypic variability among patients with hyperornithinaemia-hyperammonaemia-homocitrullinuria syndrome homozygous for the delF188 mutation in SLC25A15. *J Med Genet.* 2008;45(11):759-764.
306. Dionisi Vici C, Bachmann C, Gambarara M, Colombo JP, Sabetta G. Hyperornithinemia-hyperammonemia-homocitrullinuria syndrome: low creatine excretion and effect of citrulline, arginine, or ornithine supplement. *Pediatr Res.* 1987;22(3): 364-367.
307. Palmieri F. Diseases caused by defects of mitochondrial carriers: a review. *Biochim Biophys Acta.* 2008;1777(7-8): 564-578.
308. Shih VE, Mandell R, Herzfeld A. Defective ornithine metabolism in cultured skin fibroblasts from patients with the syndrome of hyperornithinemia, hyperammonemia and homocitrullinuria. *Clin Chim Acta.* 1982;118(2-3):149-157.
309. Camacho JA, Obie C, Biery B, et al. Hyperornithinaemia-hyperammonaemia-homocitrullinuria syndrome is caused by mutations in a gene encoding a mitochondrial ornithine transporter. *Nat Genet.* 1999;22(2):151-158.
310. Morini C, Capozzi P, Boenzi S, Rizzo C, Santorelli FM, Dionisi-Vici C. Retinal degeneration. *Ophthalmology.* 2009;116(8):1593- 1593.e1.
311. Deignan JL, Cederbaum SD, Grody WW. Contrasting features of urea cycle disorders in human patients and knockout mouse models. *Mol Genet Metab.* 2008;93(1):7-14.
312. Kasten J, Hu C, Bhargava R, et al. Lethal phenotype in conditional late onset arginase 1 deficiency in the mouse. *Mol Genet Metab.* 2013;110(3):222-230.
313. Perez CJ, Jaubert J, Guenet JL, et al. Two hypomorphic alleles of mouse *Ass1* as a new animal model of citrullinemia type I and other hyperammonemic syndromes. *Am J Pathol.* 2010;177(4): 1958-1968.
314. Sin YY, Ballantyne LL, Mukherjee K, et al. Inducible arginase 1 deficiency in mice leads to hyperargininemia and altered amino acid metabolism. *PLoS One.* 2013;8(11):e80001.
315. Allegri G, Deplazes S, Grisch-Chan HM, et al. A simple dried blood spot method for in vivo measurement of ureagenesis by gas chromatography mass spectrometry using stable isotopes. *Clin Chim Acta.* 2017;464:236-243.
316. de Cima S, Polo LM, Diez-Fernandez C, et al. Structure of human carbamoyl phosphate synthetase: deciphering the on/off switch of human ureagenesis. *Sci Rep.* 2015;5:16950.
317. Diez-Fernandez C, Martinez AI, Pekkala S, et al. Molecular characterization of carbamoyl-phosphate synthetase (CPS1) deficiency using human recombinant CPS1 as a key tool. *Hum Mutat.* 2013;34(8):1149-1159.
318. Matoori S, Leroux JC. Recent advances in the treatment of hyperammonemia. *Adv Drug Deliv Rev.* 2015;90:55-68.
319. Braissant O. Current concepts in the pathogenesis of urea cycle disorders. *Mol Genet Metab.* 2010;100(suppl 1):S3-S12.
320. Lichter-Konecki U, Nadkarni V, Moudgil A, et al. Feasibility of adjunct therapeutic hypothermia treatment for hyperammonemia and encephalopathy due to urea cycle disorders and organic acidemias. *Mol Genet Metab.* 2013;109(4):354-359.

321. Whitelaw A, Bridges S, Leaf A, Evans D. Emergency treatment of neonatal hyperammonaemic coma with mild systemic hypothermia. *Lancet*. 2001;358(9275):36-38.
322. Dhawan A, Mitry RR, Hughes RD. Hepatocyte transplantation for liver based metabolic disorders. *J Inherit Metab Dis*. 2006;29 (2–3):431-435.
323. Enns GM, Millan MT. Cell based therapies for metabolic liver disease. *Mol Genet Metab*. 2008;95(1–2):3-10.
324. Meyburg J, Das AM, Hoerster F, et al. One liver for four children: first clinical series of liver cell transplantation for severe neonatal urea cycle defects. *Transplantation*. 2009;87(5): 636-641.
325. Meyburg J, Hoffmann GF. Liver, liver cell and stem cell transplantation for the treatment of urea cycle defects. *Mol Genet Metab*. 2010;100(suppl 1):S77-S83.
326. Meyburg J, Opladen T, Spiekertkotter U, et al. Human heterologous liver cells transiently improve hyperammonemia and ureagenesis in individuals with severe urea cycle disorders. *J Inherit Metab Dis*. 2018;41(1):81-90.
327. Strom SC, Fisher RA, Rubinstein WS, et al. Transplantation of human hepatocytes. *Transplant Proc*. 1997;29(4):2103-2106.
328. Horslen SP, McCowan TC, Goertzen TC, et al. Isolated hepatocyte transplantation in an infant with a severe urea cycle disorder. *Pediatrics*. 2003;111(6 pt 1):1262-1267.
329. Stephenne X, Najimi M, Sibille C, Nassogne MC, Smets F, Sokal EM. Sustained engraftment and tissue enzyme activity after liver cell transplantation for argininosuccinate lyase deficiency. *Gastroenterology*. 2006;130(4):1317-1323.
330. Stephenne X, Najimi M, Smets F, Reding R, de Ville de Goyet J, Sokal EM. Cryopreserved liver cell transplantation controls ornithine transcarbamylase deficient patient while awaiting liver transplantation. *Am J Transplant*. 2005;5(8):2058-2061.
331. Meyburg J, Hoffmann GF. Liver cell transplantation for the treatment of inborn errors of metabolism. *J Inherit Metab Dis*. 2008; 31(2):164-172.
332. Puppi J, Tan N, Mitry RR, et al. Hepatocyte transplantation followed by auxiliary liver transplantation a novel treatment for ornithine transcarbamylase deficiency. *Am J Transplant*. 2008;8 (2):452-457.
333. Sokal EM. From hepatocytes to stem and progenitor cells for liver regenerative medicine: advances and clinical perspectives. *Cell Prolif*. 2011;44(suppl 1):39-43.
334. Sokal EM. Treating inborn errors of liver metabolism with stem cells: current clinical development. *J Inherit Metab Dis*. 2014;37 (4):535-539.
335. Cunningham SC, Kok CY, Dane AP, et al. Induction and prevention of severe hyperammonemia in the spfash mouse model of ornithine transcarbamylase deficiency using shRNA and rAAV- mediated gene delivery. *Mol Ther*. 2011;19(5):854-859.
336. Cunningham SC, Siew SM, Hallwirth CV, et al. Modeling correction of severe urea cycle defects in the growing murine liver using a hybrid recombinant adeno-associated virus/piggyBac transposase gene delivery system. *Hepatology*. 2015;62(2): 417-428.
337. Lee EK, Hu C, Bhargava R, et al. AAV-based gene therapy prevents neuropathology and results in normal cognitive development in the hyperargininemic mouse. *Gene Ther*. 2013;20(8): 785-796.
338. Wang L, Bell P, Morizono H, et al. AAV gene therapy corrects OTC deficiency and prevents liver fibrosis in aged OTC knock out heterozygous mice. *Mol Genet Metab*. 2017;120(4):299-305.
339. Wang L, Wang H, Morizono H, et al. Sustained correction of OTC deficiency in spf(ash) mice using optimized self complementary AAV2/8 vectors. *Gene Ther*. 2012;19(4): 404-410.
340. Wang L, Morizono H, Lin J, et al. Preclinical evaluation of a clinical candidate AAV8 vector for ornithine transcarbamylase (OTC) deficiency reveals functional enzyme from each persisting vector genome. *Mol Genet Metab*. 2012;105(2):203-211.
341. Viecelli HM, Thöny B. Challenges of experimental gene therapy for urea cycle disorders. *J Pediatr Biochem*. 2014;4(1):65-73.

342. Zhong L, Li S, Li M, et al. Vector sequences are not detected in tumor tissue from research subjects with ornithine transcarbamylase deficiency who previously received adenovirus gene transfer. *Hum Gene Ther*. 2013;24(9):814-819.
343. Häberle J, Rubio V. Hyperammonemias and related disorders. In: Blau N, Duran M, Gibson KM, Dionisi-Vici C, eds. *Physician's Guide to the Diagnosis, Treatment, and Follow-Up of Inherited Metabolic Diseases*. Springer, Heidelberg; 2014:47-62.
344. Dixon M, MacDonald A, White F, Stafford J. Disorders of amino acids metabolism, organic acidaemias and urea cycle disorders. In: Shaw V, Dip Dietetics P (eds) *Clinical Paediatric Dietetics*. John Wiley & Sons, Ltd, Oxford, UK, 2015:381–525
345. Qureshi IA, Letarte J, Ouellet R, Batshaw ML, Brusilow S (1984) Treatment of hyperargininemia with sodium benzoate and arginine-restricted diet. *J Pediatr* 104: 473–476.